The FPI work with a number of pharmaceutical companies on current and potential future clinical trials.
Current trials
- Alector INFRONT-3 Phase3 trial for GRN mutation carriers
- Prevail Therapeutics PROCLAIM Phase 1/2 trial of PR006 for GRN mutation carriers
- Passage Bio upliFT-D Phase 1/2 trial of PBFT02 for GRN mutation carriers
Companies with therapies for genetic FTD in development
- Biogen: C9orf72 mutation carriers [Phase 1 trial of BIIB078 currently being performed in C9orf72-associated ALS]
- Wave Life Sciences: C9orf72 mutation carriers
- Arkuda: GRN mutation carriers
- Denali: GRN mutation carriers
Other therapies being trialled (from clinical trials.gov):
- Metformin for C9orf72 mutation carriers [Single site Phase 2 study currently being performed in C9orf72-associated ALS]